Regeneron Pharmaceuticals insider transactions
Between November 2 and November 4, 2026, executives and directors of Regeneron Pharmaceuticals, Inc. filed reports detailing completed trades and proposed future stock sales. These filings reflect insider activity involving stock option exercises and the subsequent disposal of securities.
Key points
- Director George L. Sing exercised options for 15,269 shares on November 2, 2026.
- Director Huda Zoghbi filed a notice to sell 7,439 shares.
Company insider transactions
Director George L. Sing exercised options for 15,269 shares on November 2, 2026. On the same day, he sold 21,129 company shares for a total of $20,376,358.34.
Director Christine A. Poon exercised options and sold 7,830 company shares on November 2, 2026. The total sale value was $7,587,957.78 at an average price of $969.0878 per share.
Officer Joseph LaRosa exercised options and sold 4,466 company shares on the open market for $4,311,889.96. He also handled tax obligations by delivering 8,686 shares valued at $8,256,043.
Chief financial officer (CFO) Christopher R. Fenimore exercised options and surrendered 4,243 shares for tax payments totaling $4,032,971.5. Additionally, on November 2, 2026, he gifted 15 company shares.
Value of shares sold, by insider
Proposed stock sale notices and context
Director Huda Zoghbi filed a notice to sell 7,439 shares. The sale was planned following an option exercise on November 3, 2026.
Officer Jason Pitofsky filed a notice to sell 3,883 shares on November 4, 2026. A filed notice of a proposed sale does not guarantee that the sale will occur.
Earlier in October 2026, the company announced an expanded collaboration with Sanofi to develop new antibodies, which includes significant potential payments.
What to watch
Shareholders should monitor future transaction reports to see if the proposed stock sales announced by Huda Zoghbi and Jason Pitofsky are executed.
Original sources
- 144 filing, November 2, 2026
- 144 filing, November 2, 2026
- 144 filing, November 3, 2026
- 4 filing, November 4, 2026
- 4 filing, November 4, 2026
- 4 filing, November 4, 2026
- 4 filing, November 4, 2026
- 144 filing, November 4, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Regeneron Pharmaceuticals
A notification in your browser or on your phone when we publish about Regeneron Pharmaceuticals. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
